Breaking News, Promotions & Moves

Amgen Reveals Executive Transition Plans

Dr. Sean E. Harper, EVP, R&D, and Anthony C. Hooper, EVP, Global Commercial Operations, are set to retire from their roles

Amgen has announced transition plans for two of its executive vice presidents as part of a planned executive succession to address upcoming requirements. After more than 21 years of leadership in the biopharmaceutical industry, including the past 16 years with Amgen, Sean E. Harper, M.D., executive vice president of Research and Development, has decided to retire and plans to pursue opportunities in the early-stage biotechnology community. David M. Reese, M.D., currently senior vice preside...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters